Trial · NCT01944423

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

NCT01944423, Early phase 1, Completed, University of Texas at Austin; results first posted 2021-05-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine. Trials, record NCT01944423. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01944423

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
NCT number: NCT01944423
Status: Completed
Phases: Early phase 1
Enrollment: 53 participants, actual
Lead sponsor: University of Texas at Austin
Conditions: Nicotine Addiction, Panic Attack
Interventions: d-cycloserine, Pill Placebo, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
First posted: 2013-09-17
Last updated: 2021-05-19
Results first posted: 2021-05-19

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Smoking Abstinence	Assessed from week 3-29, week 29 reported	Smoking status will be assessed at baseline and each of the follow-up assessments using point prevalence abstinence (PPA) measures verified with carbon monoxide and saliva cotinine.
Secondary	Anxiety Sensitivity Mechanistic Target	Assessed from week 3-29, week 7 reported (end of treatment)	Anxiety sensitivity was assessed using the Anxiety Sensitivity Index-3, which is an 18 item measure of fear of bodily sensations. Participants rated their concern regarding the possible negative consequences of internal anxiety-related sensations. Scores range from 0-72, with higher scores indicated greater sensitivity to bodily sensations (worse outcome).
Secondary	Panic Symptoms Mechanistic Target	Assessed from week 3-29, week 29 reported (6-month follow-up)	Panic disorder severity scale is a 7-item measure assessing the severity of seven features of panic: frequency of panic attacks, distress during panic attacks, anticipatory anxiety, agoraphobic fear and avoidance, interoceptive fear and avoidance, impairment of work functioning, and impairment of social functioning. Items are rated on a five-point Likert scale ranging from 0 (none) to 4 (extreme), with a total possible score of 28. Higher scores indicate greater severity and impairment.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Smoking Abstinence	Assessed from week 3-29, week 29 reported	Intent to treat analysis	percentage of participants	NUMBER
SECONDARY	Anxiety Sensitivity Mechanistic Target	Assessed from week 3-29, week 7 reported (end of treatment)	Intent to treat analysis	unstandardized units	MEAN
SECONDARY	Panic Symptoms Mechanistic Target	Assessed from week 3-29, week 29 reported (6-month follow-up)	Intent to treat analysis	unstandardized units	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Smoking Abstinence	PSRT_DCS	8.25		percentage of participants
Smoking Abstinence	PSRT_PBO	12.35		percentage of participants
Anxiety Sensitivity Mechanistic Target	PSRT_DCS	15.37	Standard Deviation 10.38	unstandardized units
Anxiety Sensitivity Mechanistic Target	PSRT_PBO	17.80	Standard Deviation 13.77	unstandardized units
Panic Symptoms Mechanistic Target	PSRT_DCS	5.36	Standard Deviation 6.96	unstandardized units
Panic Symptoms Mechanistic Target	PSRT_PBO	5.40	Standard Deviation 5.93	unstandardized units

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	PSRT_DCS	27
Overall Study	STARTED	PSRT_PBO	26
Overall Study	End of Treatment	PSRT_DCS	21
Overall Study	End of Treatment	PSRT_PBO	20
Overall Study	1-month Follow-up	PSRT_DCS	22
Overall Study	1-month Follow-up	PSRT_PBO	19
Overall Study	4-month Follow-up	PSRT_DCS	19
Overall Study	4-month Follow-up	PSRT_PBO	16
Overall Study	COMPLETED	PSRT_DCS	19
Overall Study	COMPLETED	PSRT_PBO	17

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Chipped back bone	General disorders	PSRT_DCS	0	27	0
other	Chipped back bone	General disorders	PSRT_PBO	1	26	1
other	Pericarditis	Cardiac disorders	PSRT_DCS	0	27	0
other	Pericarditis	Cardiac disorders	PSRT_PBO	1	26	1
other	Anxiety	Psychiatric disorders	PSRT_DCS	0	27	0
other	Anxiety	Psychiatric disorders	PSRT_PBO	1	26	1
other	Anemia	Blood and lymphatic system disorders	PSRT_DCS	1	27	1
other	Anemia	Blood and lymphatic system disorders	PSRT_PBO	0	26	0
other	Migraine	General disorders	PSRT_DCS	1	27	1
other	Migraine	General disorders	PSRT_PBO	0	26	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	PSRT_DCS	0	27
Total, all-cause mortality	PSRT_PBO	0	26
Total, other adverse events	PSRT_DCS	2	27
Total, other adverse events	PSRT_PBO	3	26
Total, serious adverse events	PSRT_DCS	0	27
Total, serious adverse events	PSRT_PBO	0	26

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
32004998	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R34DA034658	Enhancing Panic and Smoking Reduction Treatment with D-Cycloserine	SMITS, JASPER; OTTO, MICHAEL W.; ZVOLENSKY, MICHAEL J.	UNIVERSITY OF TEXAS AT AUSTIN	NATIONAL INSTITUTE ON DRUG ABUSE	2013 to 2015

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
PSRT_DCS vs PSRT_PBO: deaths from any cause	Trial comparisons
PSRT_DCS vs PSRT_PBO: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01944423

GET https://conductscience.org/api/trials/v1/NCT01944423/registered

API reference For AI assistants